头孢哌酮-舒巴坦联合多西环素治疗重症肺炎患者的临床疗效分析

Clinical Efficacy of Cefoperazone-Sulbactam Combined with Doxycycline in Treatment of Patients with Severe Pneumonia

目的:分析头孢哌酮-舒巴坦联合多西环素治疗重症肺炎患者的临床疗效、炎性因子水平及不良反应发生情况.方法:选取2020年8月至2022年8月于本院接受治疗的94例重症肺炎患者作为研究对象.随机将其分为研究组(n=47,采取头孢哌酮-舒巴坦联合多西环素治疗)和对照组(n=47,采取头孢哌酮-舒巴坦治疗).比较两组患者临床疗效、白细胞计数、炎性因子[C反应蛋白(CRP)和降钙素原(PCT)]水平、症状消失所需时间、不良反应.结果:研究组患者临床总有效率(95.74%,45/47)高于对照组(80.85%,38/47),差异均有统计学意义(P<0.05);两组治疗后白细胞计数、CRP、PCT水平均明显降低,以研究组更显著,差异均有统计学意义(P<0.05).研究组患者退热、咽喉疼痛、咳嗽、头晕头疼、胸闷乏力等不适症状消失所需时间均显著短于对照组,差异有统计学意义(P<0.05).两组均未发生不良反应.结论:将头孢哌酮-舒巴坦与多西环素联合应用于重症肺炎患者,疗效确切,可更好的减轻患者炎性反应和缩短患者症状消失时间,更有利于促进患者恢复,且安全性较高.

Objective:To analyze efficacy,inflammatory factors and adverse reactions of cefoperazone-sulbactam combined with doxycycline in treatment of severe pneumonia.Methods:A total of 94 patients with severe pneumonia treated in our hospital from August 2020 to August 2022 were selected in this study.They were randomly divided into study group(n=47,treated with cefoperazone-sulbactam combined with doxycycline)and control group(n=47,treated with cefoperazone-sulbactam).The clinical efficacy,white blood cell count,inflammatory factors[C-reactive protein(CRP),procalcitonin(PCT)] level,the time required for symptom resolution and adverse reactions were compared between the two groups.Results:The total effective rate of the study group(95.74%,45/47)was higher than that of the control group(80.85%,38/47),the difference was statistically significant(P<0.05);After treatment,the white blood cell count,the levels of CRP and PCT in the two groups were significantly decreased,especially in the study group,the differences were statistically significant(P<0.05);The time required for the disappearance of fever,sore throat,cough,dizziness,headache,chest tightness and fatigue in the study group were significantly shorter than those in the control group,the differences were statistically significant(P<0.05).And there were no adverse reactions occurred in the two groups.Conclusion:The combined application of cefoperazone-sulbactam and doxycycline in patients with severe pneumonia is effective,which can better reduce the inflammatory response of patients and shorten the time of symptom disappearance,and is more conducive to promoting the recovery of patients with high safety.